Abstract
The National Cancer Institute (NCI) has a long-standing interest in evaluating and using the known advantages of molecular and functional imaging, as well as assessing the potential of novel imaging agents and modalities, to improve clinical cancer research and cancer care. In this Perspectives article, I discuss the strategies and resources being used by the NCI to foster and enhance these evaluations. Although resource and logistical challenges abound in successfully mounting these trials, many examples exist of real and potential solutions to improve the clinical evaluation process for imaging agents and modalities in the USA and in international collaborations.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Histed, S. N. et al. Review of functional/anatomical imaging in oncology. Nucl. Med. Commun. 33, 349–361 (2012).
Butowski, N. & Chang, S. M. Endpoints for clinical trials and revised assessment in neurooncolgy. Curr. Opin. Neurol. http://dx.doi.org/10.1097/WCO.0b013e328359b45e
Paul, N. S., Ley, S. & Metser, U. Optimal imaging protocols for lung cancer staging: CT, PET, MR Imaging and the role of imaging. Radiol. Clin. North Am. 50, 935–949 (2012).
Shankar, L., Menkens, A. & Sullivan, D. in Molecular Targeting in Oncology (eds Kaufman, H. L., Wadler, S. & Antman, K.) 675–692 (Humana Press, Totowa, 2008).
Beyer, T. & Townsend, D. W. Putting 'clear' into nuclear medicine: a decade of PET/CT development. Eur. J. Nuc. Med. Mol. Imaging 33, 857–861 (2006).
Cerussi, A. E. et al. Diffuse optical spectroscopic imaging correlates with final pathological response in breast cancer adjuvant chemotherapy. Philos. Transact. A Math. Phys. Eng. Sci. 369, 4512–4530 (2011).
Vesselle, H. et al. In vivo validation of 3'deoxy-3'-[(18)F]fluorothymidine ([(18)F]FLT) as a proliferation imaging tracer in humans: correlation of [(18)F]FLT uptake by positron emission tomography with Ki-67 immunohistochemistry and flow cytometry in human lung tumors. Clin. Cancer Res. 8, 3315–3323 (2002).
Dancey, J. E. et al. Guidelines for the development and incorporation of biomarker studies in early clinical trials of novel agents. Clin. Cancer Res. 16, 1745–1755 (2010).
US National Library of Medicine. ClinicalTrials.gov [online], (2011).
US National Library of Medicine. ClinicalTrials.gov [online], (2012).
US National Library of Medicine. ClinicalTrials.gov [online], (2012).
US National Library of Medicine. ClinicalTrials.gov [online], (2012).
US National Library of Medicine. ClinicalTrials.gov [online], (2012).
US National Library of Medicine. ClinicalTrials.gov [online], (2011).
US National Library of Medicine. ClinicalTrials.gov [online], (2012).
Sargent, D. J. et al. Validation of novel imaging methodologies for use as cancer clinical trial end-points. Eur. J. Cancer 45, 290–299 (2008).
Shankar, L. K. et al. Considerations for the use of imaging tools for phase II treatment trials in oncology. Clin. Cancer Res. 15, 1891–1897 (2009).
Nunn, A. Imaging biomarkers, an industry perspective. J. Nucl. Med. 49, 28N–32N (2008).
US Department of Health & Human Services. NIH Research Project Grant Program (R01) [online], (2012).
US Department of Health & Human Services. NIH Exploratory/Developmental Research Grant Award (R21) [online], (2012).
Jansen, J. F. et al. Noninvasive assessment of tumor microenvironment using dynamic contrast-enhanced magnetic resonance imaging and 18F-fluoromisonidazole positron emission tomography imaging in neck nodal metastases. Int. J. Radiat. Oncol. Biol. Phys. 77, 1403–1410 (2010).
Juhász, C. et al. Tryptophan metabolism in breast cancers: molecular imaging and immunohistochemistry studies. Nucl. Med. Biol. 39, 926–932 (2012).
US Department of Health & Human Services. Quick-Trials for Imaging and Image-Guided Interventions: Exploratory Grants (R21) [online]
US Department of Health & Human Services. Quick-Trials for Imaging and Image-Guided Interventions: Exploratory Grants (R21) [online]
Boles Ponto, L. L. et al. Stability of 3'-deoxy-3'-[18F]fluorothymidine standardized uptake values in head and neck cancer over time. Cancer Biother. Radiopharm. 25, 361–363 (2010).
Breshears, J. D. et al. Mapping sensorimotor cortex with slow cortical potential resting-state networks while awake and under anesthesia. Neurosurgery 71, 305–316 (2012).
Wali, R. K. et al. Topical polyethylene glycol as a novel chemopreventive agent for oral cancer via targeting of epidermal growth factor response. PLoS One 7, e38047 (2012).
US Department of Health & Human Services. Early Phase Clinical Trials in Imaging and Image-Guided Interventions (R21) [online]
National Cancer Institute. Translational Research Program (TRP) [online]
National Cancer Institute. Cancer Imaging Program: Phase I/II Trials [online]
Spence, A. M. et al. NCI-sponsored trial for the evaluation of safety and preliminary efficacy of 3'-deoxy-3'-[(18)F]fluorothymidine (FLT) as a marker of proliferation in patients with recurrent gliomas: preliminary efficacy studies. Mol. Imaging Biol. 11, 343–355 (2009).
US National Library of Medicine. ClinicalTrials.gov [online], (2011).
US National Library of Medicine. ClinicalTrials.gov [online], (2006).
US National Library of Medicine. ClinicalTrials.gov [online], (2010).
National Cancer Institute. Cancer Therapy Evaluation Program: Initiatives/Collaborations [online], (2012).
National Cancer Institute. Cancer Imaging Program: Cancer Tracer Synthesis Resources [online]
American College of Radiology Imaging Network. ACRIN's History [online]
American College of Radiology Imaging Network [online], (2012).
National Cancer Institute. Transforming the NCI Clinical Trials Enterprise [online]
National Cancer Institute. Biomarker, Imaging and Quality of Life Studies Funding Program (BIQSFP) [online]
US National Library of Medicine. ClinicalTrials.gov [online], (2011).
Shankar, L. K. Standardization of PET imaging in clinical trials. PET Clinics 3, 1–4 (2008).
Shankar, L. K. et al. Consensus recommendations for the use of 18F-FDG PET as an indicator of therapeutic response in patients in National Cancer Institute trials. J. Nucl. Med. 47, 1059–1066 (2006).
American College of Radiology Imaging Network. NCI Centers of Quantitative Imaging Excellence [online], (2012).
Trimble, E. L. et al. Improving cancer outcomes through international collaboration in academic cancer treatment trials. J. Clin. Oncol. 27, 5109–5114 (2009).
Eisenhauer, E. A. et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur. J. Cancer 45, 228–247 (2009).
Ford, R. et al. Lessons learned from independent central review. Eur. J. Cancer 45, 268–274 (2009).
Dancey, J. E. et al. Recommendations for the assessment of progression in randomised cancer treatment trials. Eur. J. Cancer 45, 281–289 (2009).
Schwartz, L. H. et al. Evaluation of lymph nodes with RECIST 1.1. Eur. J. Cancer. 45, 261–267 (2009).
Radiological Society of North America. Quantitative Imaging Biomarkers Alliance [online], (2012).
Clinical Trials Network [online], (2012).
US National Library of Medicine. ClinicalTrials.gov [online], (2012).
Spence, A. M. et al. NCI-sponsored trial for the evaluation of safety and preliminary efficacy of FLT as a marker of proliferation in patients with recurrent gliomas: safety studies. Mol. Imaging Bio. 10, 271–280 (2008).
US National Library of Medicine. ClinicalTrials.gov [online], (2011).
Harisinghani, M., Ross, R. W., Guimaraes, A. R. & Weissleder, R. Utility of a new bolus-injectable nanoparticle for clinical cancer staging. Neoplasia 9, 1160–1165 (2007).
US National Library of Medicine. ClinicalTrials.gov [online], (2011).
US National Library of Medicine. ClinicalTrials.gov [online], (2011).
US National Library of Medicine. ClinicalTrials.gov [online], (2012).
US National Library of Medicine. ClinicalTrials.gov [online], (2012).
US National Library of Medicine. ClinicalTrials.gov [online], (2012).
US National Library of Medicine. ClinicalTrials.gov [online], (2012).
Batchelor, T. T. et al. Phase II study of cediranib, an oral pan-vascular endothelial growth factor receptor tyrosine kinase inhibitor, in patients with recurrent glioblastoma. J. Clin. Oncol. 28, 2817–2823 (2010).
Gerstner, E. R. et al. Infiltrative patterns of glioblastoma spread detected via diffusion MRI after treatment with cediranib. Neuro. Oncol. 12, 466–472 (2010).
US National Library of Medicine. ClinicalTrials.gov [online], (2011).
US National Library of Medicine. ClinicalTrials.gov [online], (2012).
Author information
Authors and Affiliations
Ethics declarations
Competing interests
The author declares no competing financial interests.
Rights and permissions
About this article
Cite this article
Shankar, L. The clinical evaluation of novel imaging methods for cancer management. Nat Rev Clin Oncol 9, 738–744 (2012). https://doi.org/10.1038/nrclinonc.2012.186
Published:
Issue Date:
DOI: https://doi.org/10.1038/nrclinonc.2012.186
This article is cited by
-
Advances in PET Diagnostics for Guiding Targeted Cancer Therapy and Studying In Vivo Cancer Biology
Current Pathobiology Reports (2019)
-
Imaging biomarker roadmap for cancer studies
Nature Reviews Clinical Oncology (2017)
-
Metformin induces an intracellular reductive state that protects oesophageal squamous cell carcinoma cells against cisplatin but not copper-bis(thiosemicarbazones)
BMC Cancer (2014)